{"publication_id":"80f030f9-7eeb-47eb-bfb0-2a7392057a72","traces":[{"claim_id":"claim_1","claim":"Grip strength is increasingly examined as a potential biomarker of biological aging and mortality risk, yet its independent prognostic value beyond frailty constructs remains contested.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_2","claim":"We conducted an AI-assisted structured evidence synthesis of observational cohorts and systematic reviews addressing grip strength in relation to longevity, muscle function, cardiometabolic, and frailty outcomes, applying predefined inclusion criteria and cross-domain tension mapping.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_3","claim":"The evidence base for grip strength as an anti-aging target is incomplete: observational associations with longevity and cognitive outcomes are consistent but confounded, while interventional data and RCT-level causal inference remain absent.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_4","claim":"Evidence-abstraction note.** The 27 retained reference papers are not 27 independent primary clinical trials: they are review, indirect, or mechanistic source-level summaries, and none are classified as direct clinical evidence. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_5","claim":"Aging societies face a fundamental question: which modifiable biomarkers reliably predict survival across the lifespan, and which merely correlate with downstream disease burden? Grip strength, a simple bedside measure of maximal voluntary force, has attracted enormous epidemiological attention as a candidate longevity signal. Across large cohorts, lower handgrip strength is associated with higher mortality risk, with hazard ratios frequently exceeding 1.3 per standard-deviation decrement, yet the field has struggled to determine whether this association reflects causal biology or residual confounding by comorbidity, physical inactivity, and frailty (Celis-Morales 2018). The clinical stakes are high: if grip strength represents a tractable anti-aging lever, it could inform exercise prescription, pharmacological targeting, and public-health screening. Conversely, if the signal is largely epiphenomenal, investing in grip strength longevity trials may divert resources from more promising gerotherapeutic strategies. The question of whether grip strength longevity extends lifespan or merely marks individuals at risk remains unresolved, and this ambiguity has persisted despite decades of observational work. This introduction frames the problem, reviews the biological rationale, surveys the evidence landscape, and identifies the gaps our synthesis aims to address.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_6","claim":"The geroscience hypothesis posits that fundamental aging processes—cellular senescence, mitochondrial dysfunction, chronic inflammation, and proteostatic decline—drive multiple age-related diseases simultaneously, suggesting that targeting these hallmarks could compress morbidity and extend healthspan. This framework has motivated repurposing of existing drugs such as metformin and rapamycin, as well as development of novel senolytics and NAD+ precursors. Within this logic, muscle function occupies a privileged position: skeletal muscle is both a major insulin-sensitive tissue and a reservoir of amino acids critical for immune competence and wound healing. Grip strength longevity research thus emerges from two converging lines of evidence—the epidemiological observation that muscle weakness predicts mortality and the mechanistic insight that muscle-derived myokines modulate systemic inflammation and metabolic health. However, the geroscience hypothesis remains a framework, not a validated therapeutic doctrine, and its translation to clinical endpoints has been uneven. The question of whether improving grip strength longevity through exercise or pharmacology actually retards aging biology, rather than simply improving functional reserve, has been proposed but not definitively tested. This gap between mechanistic plausibility and causal proof defines the intellectual context for the present review.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_7","claim":"Grip strength longevity, as a research construct, sits at the intersection of muscle physiology, geriatric medicine, and public health. The measure itself is inexpensive, portable, and highly reproducible, making it attractive for large-scale screening. Clinically, the European Working Group on Sarcopenia in Older People established sex-specific cutoffs—27 kg for men and 16 kg for women—that are now widely used to define probable sarcopenia and trigger further evaluation (Cruz-Jentoft 2019). Below these thresholds, individuals face elevated risk of falls, disability, and postoperative complications; for instance, grip strength appears to predict anastomotic leakage after colorectal surgery (Weak 2026) and postoperative delirium in orthopedic and oncologic populations (Arita 2021, Lee 2026). Yet grip strength is not a drug; it is a biomarker, and the leap from observational association to therapeutic target requires evidence that modifying the biomarker changes the outcome. Whether grip strength longevity interventions—resistance training, nutritional supplementation, or emerging pharmacological approaches—can achieve clinically meaningful improvements in survival remains uncertain.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_8","claim":"The human trial landscape for grip strength longevity is dominated by observational cohort studies; randomized controlled trials with hard mortality endpoints are essentially absent. The available evidence derives predominantly from prospective registries linking baseline grip strength to subsequent events. Chair-based exercise interventions have demonstrated significant improvements in grip strength (P < 0.001; Chair-Based 2026), but these trials measure the biomarker, not survival. The heterogeneity of populations—from community-dwelling adults to hospitalized frail elders to pediatric malnutrition cases (Yldz 2026)—complicates generalizability. The question of whether grip strength longevity interventions reduce mortality in any specific subpopulation has not been answered by a single adequately powered RCT.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_9","claim":"Several unresolved questions temper enthusiasm for grip strength longevity as a gerotherapeutic target. First, the mechanism–function gap: it remains unclear whether weak grip strength causes adverse outcomes through direct pathways such as sarcopenia-driven metabolic dysfunction, or whether it is simply a sentinel marker of global physiological reserve and accumulated damage. Second, dose–response relationships are poorly characterized; the relationship between handgrip strength and all-cause mortality appears to be modified by systemic inflammation level, with CRP thresholds of 3, 10, and 25 mg/L each yielding distinct risk profiles (TurBoned 2026), yet optimal therapeutic targets have not been defined. Third, the duration of any intervention needed to produce survival benefits is unknown; most exercise trials last weeks to months, while the epidemiological signal accumulates over years to decades. Fourth, there is the problem of competing risks—in older adults, mortality from non-musculoskeletal causes may overwhelm any benefit derived from improved grip strength alone. Evidence suggests that grip strength longevity may be most informative as part of composite frailty indices rather than as an isolated predictor, but this hypothesis requires formal testing.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_10","claim":"The background evidence for grip strength longevity is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as the retained evidence base are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_11","claim":"The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_12","claim":"Across the retained sources, positive signals cluster around the longevity and muscle function outcome classes; null signals around the contextual adjacent evidence, muscle function and cardiometabolic outcome classes; and negative or adverse signals around the longevity, cardiometabolic and contextual adjacent evidence outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_13","claim":"The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_14","claim":"The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, direct clinical signals, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_15","claim":"This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_16","claim":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_17","claim":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_18","claim":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, frailty, immune, longevity, muscle function); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_19","claim":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_20","claim":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_21","claim":"| Contextual Adjacent Evidence | n=6; claims=113 | no extracted directional signal in 5/6 sources | 6 indirect | limited corpus depth in this outcome class |","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_22","claim":"Contextual Adjacent Evidence: n=6; claims=113; no extracted directional signal in 5/6 sources | directness: 6 indirect; main limitation: no direct clinical anchor.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_23","claim":"The relationship between grip strength and cardiometabolic risk was examined in two large observational cohort studies. Jayanama 2022 investigated the relationship between body mass index, frailty, and all-cause mortality among middle-aged and older adults, with BMI categories spanning from normal (18.5-24.9 kg/m²) to obese grade 2 or 3 (>35.0 kg/m²). Byambaa 2023 conducted a population-based study to identify anthropometric and body circumference determinants for hand grip strength across a broad adult population. Both studies employed cross-sectional or longitudinal observational designs to assess the interplay between body composition, grip strength, and cardiometabolic markers.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_24","claim":"Mechanistically, the link between grip strength and cardiometabolic outcomes may be mediated through shared pathways involving body composition, systemic inflammation, and metabolic regulation. Clinical RCTs are needed to establish whether grip strength is a causal determinant or merely a marker of cardiometabolic health. Preclinical data suggest that skeletal muscle functions as an endocrine organ, releasing myokines that influence insulin sensitivity and vascular function, providing a plausible biological substrate for the observed associations. However, the mechanistic substrate underlying the functional finding of grip strength predicting cardiometabolic risk requires further elucidation through interventional studies.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_25","claim":"Within the corpus, a notable tension exists between the findings of Jayanama 2022 and Byambaa 2023 regarding cardiometabolic outcomes. Jayanama 2022 reported negative associations (effect direction: negative) between BMI-related exposures and frailty/mortality, with multiple significant p-values, suggesting a harmful cardiometabolic trajectory. By contrast, Byambaa 2023 reported null findings (effect direction: null) for the direct relationship between grip strength and cardiometabolic determinants, indicating that grip strength may not independently predict cardiometabolic risk after accounting for anthropometric factors. This disagreement highlights the context-dependency of the grip strength-cardiometabolic relationship and underscores the need for more targeted clinical trials to resolve these discrepancies.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_26","claim":"Mechanistically, these findings support the notion that grip strength indexes broader neuromuscular and metabolic health. Chan 2022 documented parallel age-related declines in HGS and limb muscle mass, consistent with sarcopenia as the substrate linking grip weakness to adverse outcomes. Najjar 2026 demonstrated that segmental bioimpedance—reflecting tissue composition—improves prediction of HGS, reinforcing its biologic grounding in lean mass. Yldz 2026 showed that HGS responds to nutritional repletion, suggesting it is a dynamic rather than a fixed marker. Urbano 2026 provided functional data analysis of time-dependent HGS curves, identifying sex-based differences in neuromuscular activation patterns among older adults, which may mediate differential aging trajectories.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_27","claim":"Within this outcome class, the evidence is broadly convergent: all studies agree that HGS correlates with relevant physiologic parameters. However, a notable tension exists between the null-to-positive signal reported by most studies (Lee 2026; Najjar 2026; Yldz 2026; Ji 2026; Urbano 2026) and the negative age-related trajectory documented by Chan 2022. This tension—between HGS as a modifiable, responsive marker (Yldz 2026) and HGS as a trajectory-bound biomarker of aging (Chan 2022)—remains unresolved and has implications for intervention design.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_28","claim":"The evidence synthesis for frailty outcomes draws on observational cohort studies examining the relationship between grip strength and frailty status in older adult populations. This population-based investigation focused on middle-aged and older adults and reported multiple statistically significant associations between frailty measures and mortality outcomes, with p-values spanning P < 0.01 to P < 0.001 across different analytic models. Wuestney 2026 employed a multiple-methods case series design using smart home technology to detect frailty in community-dwelling older adults, while Dent 2019 provided international clinical practice guidelines for identification and management of physical frailty in frail and sarcopenic adult populations.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_29","claim":"Within the corpus, notable tensions exist regarding the strength and consistency of the grip strength–frailty association. The disagreement between these two observational cohorts highlights the challenge of translating laboratory-based grip strength assessments to real-world frailty screening. Furthermore, Dent 2019 provides guideline-level evidence that is categorized as unclear in its effect direction, creating a three-way tension across the corpus regarding whether grip strength serves as a robust standalone predictor or requires integration with other functional measures for accurate frailty classification.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]},{"claim_id":"claim_30","claim":"The quantitative findings from TurBoned 2026 demonstrated a statistically significant dose–response interaction between grip strength and inflammatory burden on mortality risk. Higher mortality rates were observed in participants with elevated CRP despite adequate grip strength, suggesting that systemic inflammation attenuates the protective association. These effect estimates were derived from multivariable models adjusting for relevant confounders across the 4.8–5.3 year observation window.","candidate_sources":[{"study":"Jayanama 2022","doi":"10.1186/s12916-022-02596-7","url":"https://doi.org/10.1186/s12916-022-02596-7"},{"study":"TurBoned 2026","doi":"10.1002/jcsm.70272","url":"https://doi.org/10.1002/jcsm.70272"},{"study":"Karahan 2026","doi":"10.1007/s40520-026-03345-z","url":"https://doi.org/10.1007/s40520-026-03345-z"},{"study":"Cui 2021","doi":"10.3389/fnagi.2021.625551","url":"https://doi.org/10.3389/fnagi.2021.625551"},{"study":"Aksoy 2026","doi":"10.1097/MD.0000000000048423","url":"https://doi.org/10.1097/MD.0000000000048423"}]}]}